How rescheduling would affect valuation

Where rescheduling stands for valuation purposes

Two different things are true at once, and a valuation has to keep them apart.

Done: Federal Register 2026-08176, effective 28 April 2026, put FDA-approved marijuana products and marijuana subject to a state medical marijuana license in Schedule III. Treasury said 280E relief for that activity will apply for the full taxable year that includes the effective date.

Not done: adult-use marijuana is still Schedule I. A companion notice set an expedited hearing on moving marijuana generally to Schedule III. It ran 11 hearing days and ended 15 July 2026. DEA published the 2,533-page transcript in late August, final briefs are in, and the chief administrative law judge will make a recommendation that the DEA Administrator is free to accept or reject. There is no deadline for either step.

The legal detail lives on the rescheduling status page. What follows is what it means for price.

The tax effect, in numbers

Illustrative, using the same store as the page on how 280E affects valuation: $5,000,000 revenue, $2,250,000 gross profit, $1,500,000 operating expenses, $750,000 EBITDA, 21% federal rate.

Scenario	Federal tax	After-tax cash
Adult-use today (280E)	$472,500	$277,500
40% medical, 60% adult-use, apportioned by revenue	$346,500	$403,500
Fully outside 280E (medical now, or adult-use if rescheduled)	$157,500	$592,500

Moving from the first row to the last adds $315,000 of annual cash. If a buyer capitalized all of it at 5x after-tax cash, the store’s value would rise from about $1.39 million to about $2.96 million. That is the theoretical ceiling. Four things keep real prices below it.

Why the full tax saving does not reach the price

1. Competition gives some of it away. Every adult-use competitor gets the same tax cut on the same day. In oversupplied states, operators with more cash tend to cut prices to win share. Part of the saving goes to consumers, not owners. The effect is strongest where price compression is already severe, and weakest in capped markets.

2. The market has refused to pre-pay. HHS recommended Schedule III in 2023 and DOJ proposed it in May 2024. Over the period when rescheduling moved forward, Viridian Capital’s median for larger public MSOs fell from 7.8x forward EBITDA in June 2024 to 5.1x in November 2025. Public investors are not paying for a tax cut until it arrives. Private buyers generally follow.

3. Litigation risk is real. Petitions against the April 2026 medical order from Smart Approaches to Marijuana, the states of Nebraska and Indiana, and a coalition of other parties have been consolidated in the D.C. Circuit. Any broader rule would face the same. A buyer underwriting five years of tax savings has to weigh the chance a court pauses or vacates the rule.

4. Old tax debts do not disappear. Treasury’s announced transition rule covers the taxable year that includes the order’s effective date, not earlier years. Trulieve still carried $668.4 million of uncertain tax position liabilities at the end of 2025. Private operators with unpaid 280E-era tax carry the same kind of burden, and buyers subtract it.

What Schedule III does not change

These matter because several of them support value today.

• Interstate commerce stays closed. Schedule III substances still need federal registration and, for a drug, FDA approval to move in interstate commerce. State markets remain walled off from each other. That protects the scarcity value of licenses in capped states, discussed on the page about license value in capped vs uncapped states. Full federal legalization with interstate trade would be a different and much larger valuation event, negative for high-cost producers in protected states.
• SBA loans remain unavailable, and bank policy is set by FinCEN’s 2014 guidance until that is rewritten. Acquisition financing does not suddenly get cheap, so buyer purchasing power does not jump. See acquisition financing options.
• State license rules are untouched. Transfer approvals, ownership caps, and residency rules continue to control who can buy.
• Federal bankruptcy is still generally closed to plant-touching businesses, so lender recovery assumptions do not improve much.

Scenario table for buyers and sellers

Scenario	What changes in a valuation	Practical deal response
Status quo: medical Schedule III, adult-use Schedule I	Medical activity valued on normal after-tax cash; adult-use on 280E cash; dual operators apportioned	Present medical and adult-use results separately
Adult-use moved to Schedule III by final rule	After-tax cash rises for all plant-touching operators; some lost to competition	Contingent consideration tied to the rule taking effect and surviving challenge
Medical order stayed or vacated by a court	Medical operators return to 280E; any refunds or reduced estimates reverse	Buyers ask for tax indemnities covering the transition year
Congress legalizes with interstate commerce	Protected-state licenses and high-cost cultivation lose value; brands and low-cost producers gain	Out of scope for most current deals; note as a long-term risk

How deals are pricing the uncertainty

Few buyers pay cash today for a rule with no date. The common structures are an earn-out or price adjustment triggered when 280E stops applying to the acquired business, a seller note whose principal steps up on the same trigger, or rollover equity so the seller shares in any rerating. Sellers deciding on timing should read the page on selling before or after rescheduling, and the rescheduling impact calculator will run the tax arithmetic on your own figures. Tax-side detail, including the transition year and apportionment, is on the rescheduling tax scenarios page.

This page is educational and is not legal or tax advice. The status described is as of mid-September 2026 and can change with a single DEA or court action.